[ { "@graph" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#pubInfo" } ] } ], "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#Head" }, { "@graph" : [ { "@id" : "http://identifiers.org/drugbank/DB01175", "@type" : [ "https://w3id.org/biolink/vocab/Drug" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "escitalopram" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] }, { "@id" : "http://purl.obolibrary.org/obo/MONDO_0008114", "@type" : [ "https://w3id.org/biolink/vocab/Disease" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "obsessive-compulsive disorder" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#association", "@type" : [ "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/MONDO_0008114" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "http://identifiers.org/drugbank/DB01175" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." } ], "https://w3id.org/biolink/vocab/aggregator_knowledge_source" : [ { "@id" : "https://w3id.org/biolink/infores/knowledge-collaboratory" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/has_population_context" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#context" } ], "https://w3id.org/biolink/vocab/publications" : [ { "@id" : "http://www.ncbi.nlm.nih.gov/pubmed/30101713" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "http://purl.obolibrary.org/obo/NCIT_C94303" } ] }, { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#context", "@type" : [ "https://w3id.org/biolink/vocab/Cohort" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "adults" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Cohort" } ] } ], "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-7641-6446" } ] } ], "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w", "http://www.w3.org/ns/prov#generatedAtTime" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2022-09-16T11:53:46.825298" } ], "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1501-1082" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "PVsL+yEE5Nsi+zVQtMT5N+DrHb4vbNHsbuhBPors+w1mbZIGCe7HmtvoJ3RQm4aUMwU14uisPy1PiKff49zxkKra6uoWE0biyS7WmZGj3Cr7gTPVKo+ebWAVKzy7F4rinpYucZOqDamc811jGl8vbOlH8vR6sqL5rnFYZYT/Glk=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w" } ] }, { "@id" : "https://w3id.org/biolink/vocab/", "http://purl.org/pav/version" : [ { "@value" : "2.3.0" } ] } ], "@id" : "http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#pubInfo" } ]